Empowered Funds LLC Purchases Shares of 33,266 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Empowered Funds LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,266 shares of the company’s stock, valued at approximately $1,376,000. Empowered Funds LLC owned 0.07% of Mirum Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in MIRM. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares in the last quarter. R Squared Ltd purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth $69,000. Avanza Fonder AB bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $189,000. Y Intercept Hong Kong Ltd bought a new position in shares of Mirum Pharmaceuticals during the third quarter worth $215,000. Finally, Creative Planning purchased a new position in Mirum Pharmaceuticals during the third quarter valued at $249,000.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the transaction, the senior vice president now owns 2,926 shares in the company, valued at $125,291.32. The trade was a 20.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joanne Quan sold 6,969 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $45.86, for a total value of $319,598.34. Following the transaction, the insider now directly owns 5,649 shares in the company, valued at approximately $259,063.14. This represents a 55.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,915 shares of company stock worth $1,897,920 over the last quarter. Insiders own 22.87% of the company’s stock.

Wall Street Analysts Forecast Growth

MIRM has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup raised their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $50.04 on Monday. The business’s 50 day moving average price is $45.31 and its 200-day moving average price is $42.66. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $53.49. The company has a market cap of $2.40 billion, a P/E ratio of -24.77 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.